These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 24462359)

  • 1. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
    Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
    Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.
    Wang X; Teng Z; Wang H; Wang C; Liu Y; Tang Y; Wu J; Sun J; Wang H; Wang J; Lu G
    Int J Clin Exp Pathol; 2014; 7(4):1337-47. PubMed ID: 24817930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.
    He Q; Gao Y; Zhang L; Zhang Z; Gao F; Ji X; Li Y; Shi J
    Biomaterials; 2011 Oct; 32(30):7711-20. PubMed ID: 21816467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antitumor efficacy of irinotecan-loaded galactosyl modified lipid bilayer-coated mesoporous silica nanoparticles against hepatocellular carcinoma cells].
    Chen X; Zhang XX; Li FF; Zhao YN; Jia Z; Gan Y; Li J
    Yao Xue Xue Bao; 2014 May; 49(5):718-25. PubMed ID: 25151746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Efficacy against Drug-Resistant Tumors Enabled by Redox-Responsive Mesoporous-Silica-Nanoparticle-Supported Lipid Bilayers as Targeted Delivery Vehicles.
    Yang S; Zhang B; Zhao X; Zhang M; Zhang M; Cui L; Zhang L
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary study on pH-sensitive lipid bilayer-coated mesoporous silica nanoparticles as a novel drug carrier for antitumor drug].
    Li FF; Zhang XX; Guo SY; Gan Y; Li J
    Yao Xue Xue Bao; 2013 Feb; 48(2):291-7. PubMed ID: 23672029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled synthesis and size effects of multifunctional mesoporous silica nanosystem for precise cancer therapy.
    Ma B; He L; You Y; Mo J; Chen T
    Drug Deliv; 2018 Nov; 25(1):293-306. PubMed ID: 29334793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
    Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
    Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles.
    Pan L; Liu J; He Q; Wang L; Shi J
    Biomaterials; 2013 Apr; 34(11):2719-30. PubMed ID: 23337327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells.
    Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC
    Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
    Yan Y; Fu J; Wang T; Lu X
    Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.
    Ling G; Zhang T; Zhang P; Sun J; He Z
    Int J Nanomedicine; 2016; 11():4077-91. PubMed ID: 27601896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
    Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
    Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y; Lee SH; Sinko PJ
    Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergism through combination of chemotherapy and oxidative stress-induced autophagy in A549 lung cancer cells using redox-responsive nanohybrids: a new strategy for cancer therapy.
    Lu HY; Chang YJ; Fan NC; Wang LS; Lai NC; Yang CM; Wu LC; Ho JA
    Biomaterials; 2015 Feb; 42():30-41. PubMed ID: 25542791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance.
    Huang IP; Sun SP; Cheng SH; Lee CH; Wu CY; Yang CS; Lo LW; Lai YK
    Mol Cancer Ther; 2011 May; 10(5):761-9. PubMed ID: 21411714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.